It is important to acknowledge that communication about trials among participants is not new. However, social media dramatically raise the stakes by facilitating communication that can reach large audiences at low or no cost without respect to geographic boundaries. In-person or local communication between participants is more serendipitous and limited in scope, whereas social media can facilitate communication between individuals who otherwise would be unlikely to meet. Accordingly, social media amplify concerns raised by participant communication and demand distinct mitigation strategies. Although there has been substantial attention in the ethics literature to research on data collected using social media platforms and to Internet-related research more generally, [8] [9] [10] the interplay of social media with traditional clinical trials has received less attention.
Here, we propose the Social Media ADEPT framework to enable investigators, in collaboration with patient partners, to address the concerns raised by participants' online communication about trials. The framework encourages a structured and systematic approach, including the following steps: Assess when and how social media are likely to pose risks for a study and plan accordingly, Design studies to minimize these risks, Educate participants about their responsibilities to promote study success and avoid harmful social media use, Preempt problems by offering alternative mechanisms for
Cancer December 15, 2018 participants to have their concerns addressed, and Take additional steps if necessary. In what follows, we describe the benefits and limits of this approach, concluding that this is a promising model to protect participants and trial integrity from the downsides of social media communication while retaining the benefits.
WHAT COULD GO WRONG? AN ILLUSTRATIVE EXAMPLE FROM AN ONGOING CLINICAL TRIAL
To better understand some of the issues that may arise, consider an ongoing breast cancer trial at our institution for patients currently free of disease but at risk of recurrence by virtue of having disseminated tumor cells (CLEVER, a phase 2 pilot trial of hydroxychloroquine, everolimus, or the combination for prevention of recurrent breast cancer; clinicaltrials.gov identifier NCT03032406). 11 Trial participants are randomized into 1 of 4 arms, comprised of 2 oral drugs currently approved by the US Food and Drug Administration for other indications but under evaluation in the study for their ability to eradicate these residual tumor cells when used either separately (arms 1 and 2), in combination (arm 3), or in combination with a delayed start (arm 4). The primary endpoint is feasibility of the approach, and secondary endpoints are toxicity and preliminary efficacy. For reasons of cost and practicability, the trial is open-label. To assess the optimal duration of therapy and avoid potentially unnecessary treatment, participants have their bone marrow retested after 6 months. If the bone marrow is negative for residual cancer cells, then study treatment ends. If it is not, then participants-regardless of their previous assignment-receive 6 months of the 2 study drugs in combination.
Early on, several participants posted information about the study on a pre-existing, open Facebook page for patients with breast cancer, which enhanced nationwide recruitment and was welcomed by investigators. Subsequently, some participants created a closed (ie, permission-only) Facebook group exclusively for trial participants. The investigators were not invited to join but learned of the closed group's existence from participants. They became concerned about harm to both study participants and the trial overall should participants share information about study assignments and test results. Because participants are aware of their study assignment and know whether their results indicate bone marrow clearance, investigators worried that the participants might develop anecdote-driven theories about whether or not the drug regimen to which they were randomized "worked" and share those theories online. Such information sharing might lead current participants to be upset about their treatment assignments and to reconsider whether they want to continue on study and/or seek the drug(s) that they believe to be "winning" from another source. In addition, sharing such information could color the peer-to-peer advice given to individuals considering trial enrollment about whether they ought to agree to be randomized to a "losing" arm. If either or both occurred, then there could be important implications for scientific integrity and participant interests.
The investigators were sensitive to the reality that patients facing the anxiety of a cancer relapse and burdens of study participation understandably would want to maximize their chances of individual success and avoid assuming burdens without benefit. Yet they were also aware that participant speculation and theorizing in the midst of a trial based on anecdotes of individual experience could lead to erroneous and premature conclusions that would inappropriately bias personal decision-making and would be counterproductive to participant interests. This is because making valid judgments requires both robust aggregate data from an adequate sample size and careful procedures and safeguards against bias. Moreover, such speculation and theorizing can undermine the broader goal of advancing therapy for future patients, such that participants could be exposed to research risks and burdens without sufficient countervailing social benefits. Therefore, the investigators determined that the Facebook group could not be ignored and sought advice about how to proceed. Their particular solution is discussed below, but the challenges they face exemplify a broader problem.
PARTICIPANT ACTIVITIES WITH POTENTIALLY ADVERSE CONSEQUENCES
The fundamental problems that may result from communication between trial participants (and be intensified by social media) are twofold and interconnected: 1) reduced scientific value, and 2) risks to participants.
2,3
Currently, we lack systematic data about precisely how and how frequently these problems arise, but the review of online postings cited above, 2 as well as investigator experience, suggest various mechanisms.
One of the most substantial concerns is that participants might share advice about how to avoid triggering valid and well-tailored exclusion criteria that otherwise would bar some individuals from enrolling in a desirable trial or jeopardize their continued participation. In open-label studies, participants may attempt to predict Cancer December 15, 2018 whether a treatment is efficacious before trial completion and act upon that prediction, as occurred in the cancer trial described above. In blinded studies, participants might describe their study medications to one another and detail their side effects, potentially leading to their own unblinding as well as unblinding of study staff and investigators. For either type of study, should participants conclude-rightly or wrongly-that they are on a placebo, standard care, or the "losing" arm, they may be less vigilant about adhering to study requirements or drop out early and encourage others to do the same. These conversations may occur even before enrollment, as patients remind one another that if they enroll and are unhappy with their trial assignment, they can always quit. 2 Although this is their right, 12 it may lead to incomplete data, bias study results, or reduce observed follow-up time and study power. If a study involves interventions that are available elsewhere, then participants who are unhappy with their assignment also might coach one another to seek access through other avenues. In some cases, study participants may make arrangements to share active medications with others who believe they are on either placebo or less intensive or effective study treatments. Conversely, if participants perceive themselves to be on a "winning" arm, then they may under report side effects to avoid dose reductions or discontinuation from study therapy.
In these examples, participants would be making decisions without the benefit of the rigorous, statistically sound analysis needed to make informed judgments about their best interests. And, in each instance, these behaviors would make such rigorous analysis of trial data more difficult.
PROTECTING STUDY PARTICIPANTS AND TRIAL INTEGRITY
Addressing the concerns raised by social media in the context of clinical trials is in the interest of participants, future patients, and investigators. The 5-part Social Media ADEPT framework is intended to encourage stakeholders to work collaboratively to meet these challenges. Although this framework has not yet been empirically tested for efficacy, given the lack of guidance currently available on these topics, ADEPT offers an important and practical step forward. Implementation will entail an investment of time and resources-and we readily acknowledge that investigators already face many demands-but steps taken upfront can minimize problems later on. Moreover, implementing the framework should become easier over time as resources are developed that may be used across studies, such as educational tools for participants and standard consent language around social media communication. Figure 1 depicts key questions to guide each step in the process.
Assess
First, to develop an appropriately responsive social media mitigation plan, investigators should assess how participants' social media use could be problematic in a contemplated study. Of course, this demands that trial leadership build the sort of teams (including patients, patient advocates, and prior research participants who can advise on these issues) that will allow them to stay up to date on current social media platforms and how they may be used, as these factors are in constant flux. However, none of what follows is specific to a particular platform, and there is adequate flexibility to account for inevitable changes in the media of interest.
Social media are particularly likely to raise challenges for trials recruiting from highly engaged patient communities, such as those with rare diseases or well established advocacy groups. This is because these communities engage in substantial online discussion about all aspects of their condition and care, and research participation will be no different. It is also reasonable to expect that, when recruitment relies heavily on social media, whether by design or happenstance, online discussions of the trial will continue after enrollment. 13, 14 That said, given the ubiquity of social media use, investigators should assume that most prospective and enrolled participants will be social media users; the only question is how motivated they will be to connect and communicate about the study online. Thus, lacking evidence to the contrary, investigators should assume that they need a mitigation plan.
Design Collaboratively
The next step is to design studies that adequately account for participant interests and are maximally "patient-centered," beyond the typical considerations of minimizing risk. Designing trials with participant needs and perspectives in mind is both the right thing to do and should help facilitate study adherence, because the requests made of participants will have been vetted and found to be reasonable. It also should help generate an esprit de corps among participants who are invested in the study and dedicated to its successful completion. 3, 15 When participants are treated as partners, the study is theirs, too; in that case, they should be less likely
Cancer December 15, 2018 to engage in damaging behaviors online. 5 Therefore, rather than treating participants as "mere data sources whose personal needs and concerns get in the way of the research process", 3 emphasizing their essential role and engaging them about how their data will be used to promote science may contribute to a greater sense of study ownership.
To understand the importance of this engagement, consider Rebecca Dresser's observation that, "[w]hen their personal interests conflict with the demands of participation, some subjects surreptitiously break the rules". 3 If participation in a study is truly against an individual's interests because the risks are too great and burdens too high, she should be excluded from enrollment. But what Dresser's quote highlights is that research often involves certain tradeoffs between the interests of future patients and those of current participants, who might, for example, prefer to receive an experimental intervention without any of the typical constraints of a clinical trial, if that option were available. Although many participants also have altruistic motivations, it is natural to hope for direct medical (or other) benefit. Consequently, participants may seek to advance their personal interests in ways that are unlikely to be successful in achieving that goal for the reasons described above and that may be to the detriment of the trial-although they may be unaware of either problem. Again, these are precisely the sorts of behaviors that can be exacerbated by social media communication.
Including the participant perspective in the trial design process from the start, as encouraged by the patient-engaged research movement, 16 can help minimize problematic behaviors by aligning participant interests with scientific interests to the extent possible. Such consultation with patients and patient advocates can identify concerns that may arise for those who would contemplate enrollment and lead to the incorporation of trial elements that are more palatable to participants, decreasing problematic social media communication by decreasing the perceived need for it. For example, researchers should adopt the least restrictive eligibility criteria compatible with safety and scientific considerations, as this will permit enrollment by the widest range of interested patients, thereby reducing the impetus for communications about gaming eligibility criteria while having the salutary effect of generating data with broader clinical relevance and generalizeability. 17 Studies using crossover designs also may mitigate concerns that social media communications will lead to nonadherence or other problems, because everyone who enrolls eventually will receive the intervention of interest; however, crossover designs may preclude the ability to measure the effects of study interventions on long-term outcomes, such as overall survival. It will not always be possible to perfectly align participant and scientific interests in a way that offers a failsafe mechanism to avoid social media challenges. For example, to generate the sort of rigorous data needed for medical advancement, we will not be able to totally abandon randomization, placebos, blinding, or certain other design elements that participants may find unappealing. Thus, the subsequent steps of the ADEPT model will remain important in most cases. Nevertheless, cultivating a cooperative approach with patients and advocates during study design to decide the most important questions to ask and assess which type of participation will be amenable can be one of the best approaches to mitigate the risks of online communication. Cancer December 15, 2018
Educate
Once investigators have designed the most palatable trial possible, the next step in their social media plans should be to educate participants about the potentially negative impact of social media communications. Some participants may not realize the damage that discussing their participation online can cause 2 and will avoid it if simply informed of the practical consequences. Some tools already exist for this purpose, 18 and education should be built into the ongoing consent process.
14 However, the effectiveness of educational interventions will likely depend on participants' perspectives and motivations for trial participation. Some participants may believe they have a "right" to engage in whatever online discussions they choose. One participant who had been active on social media during a study stated that, "if I'm going to be poked and prodded, I'm going to be here blabbing about it." 5 Others, however, may be inclined to self-regulate if they are particularly motivated by advancing medicine for future patients.
As part of education, it is crucial to explain that when participants consent to participate in a study, they accept an ethical responsibility to help promote the creation of useful knowledge; after all, that is the reason why research is carried out, although it should also strive to maximize benefits to participants. At a minimum, participants have an obligation to be truthful with investigators, adhere to study requirements, and take seriously their commitment to participate through completion even if they are assigned to a "less desirable" study arm (which may turn out to be the more desirable arm once data are analyzed). 3 In this vein, they have an obligation to avoid behaviors, including problematic social media use, that might hinder others' ability to fulfill their obligations to research or that could diminish the value of others' contributions by creating problems for study integrity.
So long as care is taken not to obscure the voluntariness of research participation or the participant's right to withdraw from a study, both of which are legally protected, 12 it is appropriate and commonplace for consent materials and discussions to emphasize the mutual obligations of participants and researchers. This provides an opportunity to discuss social media behaviors to be avoided and their consequences, just as informed consent may explain the need to attend all study visits or notify study staff about adverse events. Efforts to educate participants about how scientific evidence is generated, including the need to study a sufficiently large sample size for a sufficiently long time to draw accurate conclusions, also can help participants understand how precarious it is to change their behaviors based on information gleaned from social media, as well as ways in which social media discussions may undercut their own contributions to research. In each of these areas, peer-to-peer education also can be an important tool.
Many of these educational strategies are being used successfully in the breast cancer trial described above. For example, upon learning of the closed Facebook group, investigators sought input from an established group of patient advocates. Investigators then discussed their concerns with the creator of the Facebook group, individual participants during study visits, and participants at large through an institutional review board-approved letter requesting that participants share neither the arm to which they have been assigned nor their bone marrow aspirate results. Because of the thoughtful way in which communications took place, participants have been understanding of the concerns, accepting of requested restrictions, and proactive in self-monitoring group activities. Although this is a good outcome, especially as it relates to continuous engagement and education of both investigators and participants as a study proceeds, working with patients at earlier stages to identify potential concerns and how to address them would be an even stronger approach.
Preempt
Beyond education, investigators may have the opportunity to offer alternative settings for communication, potentially preempting problematic social media use that otherwise might occur. Social media use by research participants reflects, among other things, a desire to connect to others with similar experiences. When investigators recognize this, they can develop other ways to meet participants' need for connection, for example, establishing moderated, online discussion groups to provide enrolled and prospective participants reliable information and real-time answers to their questions. 2, 5 It is possible that participants would prefer these "official" spaces, or at least would view them as adequate to fulfill their needs, particularly if they are moderated by a third party without a particular stake in the research. That said, having study staff involved provides the opportunity to identify and redirect problematic discussions. Preemption may not eliminate problematic social media use if patients are determined to discuss things away from a monitored environment, but it is a way to acknowledge participants' desire to communicate while also minimizing less desirable types of online discussions.
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Take Other Steps as Needed
For many studies, the steps described above-Assess, Design collaboratively, Educate, and Preempt-will likely be adequate. When social media use continues to cause problems, however, investigators may need to Take additional steps. In these cases, care should be taken to escalate the response only to the extent necessary and to maintain cooperative relationships between the study team and participants. Potential steps for investigators to consider, in collaboration with institutional review boards and patient partners, include the following:
Objective monitoring
In the event of serious concern about the gaming that may result from social media conversation that persists despite efforts to educate participants and other protective steps, investigators may find it necessary to use additional objective measures of eligibility, adherence to study interventions, and abstention from unassigned or prohibited products, rather than relying exclusively on participant self-reports. For example, intermittently measuring participants' drug levels could determine whether a study arm has been contaminated by patients surreptitiously taking drugs to which they are not assigned. Although objective measures can add to a study's expense and logistical burden, where they are available, they promote scientific integrity and can generate more finely tuned data that will be useful for future patients. Thus, such measures can be important tools if used in a manner that is not off-putting to research participants.
Restrict and enforce
As participants are educated about the potential negative impact of social media communications on research, the natural corollary is to ask them to refrain from such behaviors. Beyond mere requests, however, investigators may consider outright prohibition, treating adherence to codes of conduct that restrict social media discussion of trial participation as an eligibility criterion and element of study compliance. It is common for participants to be told that systematic noncompliance with protocol requirements will be grounds for removal from a study, and the same general principle can apply here, so long as eligibility criteria are reasonably related to important study goals and participant protections. Thus, assuming adequate education about the importance of avoiding problematic online communications, warnings about the consequences of continued nonadherence, and adequate opportunities to address behavior, it can be ethically permissible to remove participants who persistently engage in detrimental online behaviors. 15 Ethical permissibility, of course, is distinct from an ethical recommendation or requirement. We view study removal as a last resort, an option that should not be considered unless other interventions have failed and the participant's activity clearly threatens study integrity, his or her own safety, or the safety of others.
There are also other practical concerns suggesting that outright restriction and enforcement ought to be used only with the greatest care. From a legal perspective, although a mere request or recommendation to avoid problematic social media use is likely acceptable, restrictions can implicate free speech rights when imposed by government institutions, such as public universities. 19 Participants also may find outright restrictions an unacceptable barrier to their enrollment, causing them to view researchers as unduly controlling and out of touch. Another problem is that it may be difficult to detect noncompliance with social media restrictions, which may lead to unfairness if only certain participants are removed for noncompliance despite noncompliance being widespread. This raises important questions about monitoring participant use of social media and bodes in favor of approaches that use collaboration rather than "punishment."
Intervene and correct
If participants disclose problematic social media usetheir own or others-to the study team, as occurred in the cancer trial described above, then investigators must seek more information. Have participants been encouraged to be dishonest about eligibility criteria? Do the discussions suggest that study adherence is a concern or that participants are not appropriately reporting adverse events? Have participants been unblinded? What are they telling others who are contemplating enrollment? The answers to these questions will dictate the appropriate response. In the breast cancer study example, participants in the Facebook group agreed-as part of the broader response-to allow a patient advocate to monitor activities, check accuracy, and remind participants of the consequences of divulging information about their study experience.
Some have suggested that investigators should go even further and consider tracking certain websites to identify content that potentially could affect the conduct of their study and its outcome. 2 However, this would impose a heavy burden on study teams and even may risk unblinding them. 13 Such monitoring might feel overly intrusive to participants and, in many cases (such as when discussions occur in closed online groups), would Cancer December 15, 2018 be impossible.
3,13 Accordingly, we agree with others who have argued that investigators have no affirmative obligation to surveil participants' social media use. However, they should avoid willful ignorance and take steps (ideally, in collaboration with patient partners) to correct misinformation or other damaging communications when they become aware of them. 14 Investigators may need to remind certain participants about the negative impacts of their social media behaviors, and it may be necessary to provide further education to the entire study population. Where misinformation has been spread, investigators will need to counter it, perhaps in a letter to all study participants or during 1-on-1 visits. It also may be advisable for investigators to invite participants to ask questions of the study team, maybe in a group forum, particularly if it seems clear that the social media discussions were rooted in confusion, anxiety, or other concerns that the team can address head-on. In severe cases in which it becomes evident that the study's integrity has been irreparably compromised, it may be necessary to throw out the data and begin recruitment anew. This is clearly the worst outcome, for both investigators and participants, and ideally can be avoided by taking the various preventive measures described above.
Conclusion
That trial participants may use social media to communicate in ways that could have an impact on clinical trials should no longer come as a surprise to investigators. We suggest that the potential negative impacts of such communication likely can be minimized through implementation of our Social Media ADEPT approach. Because discussion of trial participation on social media is often motivated by understandable participant self-interest, dissatisfaction with the terms of study participation as defined by researchers, and desire for community, the best approach to counter the negative impacts of such communication is likely collaboration with patient partners to align trial design with participants' interests to the maximum extent possible. More broadly, using the ADEPT steps in combination offers a robust opportunity to protect participants, their contributions to research, and study integrity; the idea is to maximize these goals, certainly not to "control" or exert authority over participants for its own sake.
Prospective evaluation of the Social Media ADEPT framework in practice is warranted to assess its impact on clinical trials processes and outcomes and to refine the approach. Empirical research also will be important to better understand the full range of motivations of participants engaged in social media communications about the studies in which they are enrolled, as well as approaches that would be most effective in encouraging helpful rather than harmful social media use.
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